# Nociceptors and the Sodium Channels of Pain

> A sodium-channel change can alter a nociceptor's spike initiation, so what the neuron does depends on how many channels are available at rest, not only on how easily they open. Human sodium-channel genetics gives pain biology its cleanest loss-of-function evidence: loss of SCN9A removes pain, and other variants in the same gene cause pain syndromes. The change can act through channel number, gating and availability, sometimes by shifting the resting potential. This lesson works through that genetics, including the Nav1.9 variants that break the rule that more channel current means more pain, and then takes a Nav1.8 blocker from a fitted channel curve to a phase 3 outcome. It also sorts molecular labels from conduction classes from functional states and reads two complementary mouse lesion experiments. You will be able to calculate residual channel current from a concentration curve, say why that is not neuronal silence, and weigh competing accounts of Nav1.7-null analgesia.

Course: Sensory Systems (Temperature, pain and itch). Level: advanced university and graduate. About 36 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/nociceptors-and-sodium-channels/

Builds on: Five Ways to Turn a Stimulus into a Current · Sensory Neurons by Their Genes: the Atlas Era · Hot, Warm, Cool and Cold

## What you'll learn

- Explain how recessive and gain-of-function SCN9A variants, and the Nav1.9 variants in Huang and colleagues (2017), produce opposite behavioural consequences; for the depolarizing Nav1.9 variants, trace membrane potential, subtype-specific availability and firing, and distinguish these from effects on terminal transmission and on reported pain.
- Calculate residual Nav1.8 current from a fitted concentration-response curve and state what that number does not show about a neuron.
- Separate molecular label (CGRP, MRGPRD, Calca, CHRNA3), conduction class (Aδ, C) and functional state (mechanoinsensitive, sensitized) when describing nociceptor populations.
- Read function from the complementary lesions in Cavanaugh and colleagues (2009), including why the deletion-from-birth comparison matters.

**Three families in northern Pakistan contained people who had never experienced pain, and the cause was two broken copies of one sodium-channel gene. The sodium-channel blocker that reached patients in 2025 targets a different channel.**

Those two sentences set the problem. Human genetics nominated Nav1.7; the drug that worked blocks Nav1.8. Why the two came apart is the subject of this lesson: the end of the Nav1.8 section returns to this puzzle and explains why a genetic requirement does not guarantee that a particular inhibitor will relieve pain.

You have met the groundwork in [touch and pain](https://stemhop.com/lessons/touch-and-pain/), which separates nociception from pain, sorts fibres by diameter and velocity, follows the spinothalamic crossing, and takes transient receptor potential vanilloid 1 (TRPV1), transient receptor potential melastatin 8 (TRPM8), transient receptor potential ankyrin 1 (TRPA1) and Piezo2 to the level of necessity. This lesson picks up where that one stops. Two questions run through everything that follows: which molecularly defined nociceptors do what, and what human sodium-channel genetics and pharmacology have actually shown.

## What a sodium-channel result can and cannot predict

> **The one idea to carry through this lesson.** A sodium-channel change reaches behaviour through what it does to the neuron’s spike initiation, and that depends on how many sodium channels are **available** at the resting potential — not sitting inactivated, and so free to open — and not only on how easily they open. So more current and less current do not predict more pain and less pain. Ask three questions in order: what did the change do to the channel, what did that do to the resting potential and to channel availability, and only then what did that do to firing.
>
> **Scope.** This is a statement about spike initiation in nociceptors carrying Nav1.7, Nav1.8 and Nav1.9, in the preparations this lesson reads, and it does not say what a person feels. Release at the central terminal is a second route from channel to behaviour. Keep the levels of evidence apart as you read: a channel recording measures current, a neuronal recording measures firing, a mouse withdrawal measures a reflex, and the human studies and clinical phenotypes include reports of pain, which the surgical trials quantify with SPID48. *Where the idea stops*, at the end, lists the rest of the limits.

## Three channels, one spike

**Film transcript: Three Channels and the Availability Budget**

### Film transcript: Three Channels and the Availability Budget

Three sodium channels sit in a nociceptor. Which of them builds the spike? Nociceptor spikes draw on three channels concentrated in these neurons. Two of them are Nav1.7 and Nav1.8. The third is Nav1.9. The last two are tetrodotoxin resistant. That is how their currents are isolated in a recording. Those two carry pore residues that weaken the toxin's grip, so the toxin leaves them conducting. and a V1 .7 and N, a V1 .8 contribute to the spike itself. Nav1.9 mainly sets the resting potential and subthreshold excitability. Keep two kinds of current apart. A transient current rises and then inactivates within milliseconds. A persistent current stays appreciable while the membrane sits still.

Its inactivation is slow or incomplete, not absent. Nav1.9 supplies a persistent current. Its slow gating suits a role at rest rather than in the upstroke. Now the quantity this lesson turns on. Availability is the fraction of sodium channels not already inactivated. Channels sitting in the inactivated state cannot open when the membrane depolarizes. Availability depends on the voltage the membrane has been resting at. Hold one voltage long enough and availability settles on this curve. The curve has a half-inactivation voltage and a slope factor. For Nav1.7-like channels the slope is about seven millivolts. Other subtypes, especially Nav1.8, need their own measured curves.

The curve runs downhill. The more depolarized the rest, the fewer channels are left to open. Two nociceptors carry the same channels. One rests low, one rests high. Which has more available? The low one. About two-thirds of those channels are available, against about one-fifth. Now give each neuron the same small depolarization, and hold it there. The low one keeps about three-quarters of its availability. The high one keeps about half. It was already low on the curve, so the same step costs it proportionally more. Those midpoints are illustrative. For a real neuron the midpoint is a measurement, not an assumption. So depolarization does two opposite things at once.

It closes the gap to threshold, and it costs availability. That is the order to ask in. What happened to the channel, then to rest and availability, then to firing. Treat availability as a budget, but a reversible one. Channels recover from inactivation when the membrane goes negative again. The budget shows what a step costs, not whether the neuron fires.

From the film

- Nav1.7 and Nav1.8 contribute to the spike itself, while Nav1.9 mainly sets the resting potential and subthreshold excitability.
- Availability is the fraction of sodium channels not already inactivated, and it falls as the resting potential becomes more depolarized.
- Depolarization closes the gap to threshold but costs availability, so ask what happened to the channel, then to rest and availability, then to firing.

Nociceptor spikes draw on three channels concentrated in these neurons: Nav1.7 (gene SCN9A), Nav1.8 (SCN10A) and Nav1.9 (SCN11A), the last two tetrodotoxin resistant, which is how their currents are isolated in a recording. Nav1.7 and Nav1.8 contribute to the spike itself, while Nav1.9 mainly sets the resting potential and subthreshold excitability. How sodium channels activate and inactivate is the business of [the action potential](https://stemhop.com/lessons/action-potential/) and [ion channels as receptors](https://stemhop.com/lessons/ion-channels-as-receptors/).

Two kinds of sodium current matter here, and keeping them apart is most of the lesson. A **transient current** rises when the membrane depolarizes and then inactivates within milliseconds; that is the current a spike is built from. A **persistent current** stays appreciable while the membrane sits still, because its inactivation is slow or incomplete rather than absent. What persists is a population current: individual channels keep opening, closing and inactivating under it. Nav1.9 supplies a persistent current, which is why it pulls on the resting potential rather than on the upstroke.

Now the quantity the rest of the lesson turns on. **Availability** is the fraction of voltage-gated sodium channels not sitting in the inactivated state, and so free to open when the membrane depolarizes. It depends on the voltage the membrane has been resting at, because inactivation accumulates while the membrane sits depolarized and channels recover from it only at negative voltages. Hold the voltage steady long enough and availability settles at a value read off a Boltzmann curve,

> **h(V) = 1 / (1 + exp[(V − V½) / k])**

with V½ the half-inactivation voltage and k about 7 mV for Nav1.7-like channels. Every voltage below is a held, steady-state one. The curve runs downhill: the more depolarized the rest, the fewer channels are left. So depolarization does two opposite things at once. It moves the membrane closer to threshold, which helps a neuron fire, and it costs availability, which removes the current the spike is built from.

One curve does not cover the whole neuron. Nav1.8 half-inactivates at far more depolarized voltages than Nav1.7, so a curve drawn for Nav1.7-like channels describes the channels that depolarization takes out first, not every sodium channel in the cell.

**Predict.** Two nociceptors carry the same channels. One rests at −70 mV, the other at −55 mV. Which has more sodium channels available, and which one stands to gain from a small depolarization? Commit to an answer before reading on.

> **Check your prediction.** Take an illustrative V½ of −65 mV and k of 7 mV, a curve in the range reported for Nav1.7-like channels — the TTX-sensitive ones, not the whole mixture the neuron carries.
>
> - at −70 mV: h = 1/(1 + e−5/7) = **0.67**, so about two-thirds of those channels are available;
> - at −55 mV: h = 1/(1 + e10/7) = **0.19**, so about one-fifth are.
>
> Now give each neuron the same 5 mV depolarization and hold it there. The neuron starting at −70 mV keeps about three-quarters of the availability it had; the one starting at −55 mV keeps about half. So the same step costs the depolarized neuron proportionally more: it was already low on the curve, where there is less left to lose.
>
> Stop there. You have a cost, in one subtype, for each cell — not what either cell does, because both steps also close the gap to a threshold that can itself move, and firing draws on the rest of the neuron’s conductances. The arithmetic says which neuron can better afford the step. Its direction holds whatever midpoint you assume; its size does not, because the midpoint for a real neuron is a measurement.

## People who cannot feel pain, and people who feel too much

Human sodium-channel genetics gives pain biology its cleanest loss-of-function evidence, because the mutations are inherited, the phenotypes are extreme, and the channel can be put in a recording rig.

Cox, Woods and colleagues (2006) mapped congenital inability to experience pain in three consanguineous families from northern Pakistan and found three different homozygous nonsense mutations in SCN9A.

**Predict.** You have the pedigrees and three different nonsense alleles in one gene. What measurement would you insist on before believing that this gene causes the phenotype?

> **Check your prediction.** Put the mutant channel in a cell and look for current. Linkage and segregation tell you the variant travels with the phenotype; they cannot tell you the protein stopped working, and a nonsense allele is not by itself proof of a dead channel.
>
> The authors did exactly that. Expressed with accessory subunits in HEK293 cells — a heterologous system in which wild-type and mutant constructs are compared against the recording background in control-transfected cells — the mutant human channels produced currents no greater than background. Loss of this channel, loss of pain, with the genetic argument and the biophysical one pointing the same way.
>
> Note what the assay does and does not reach. No current above background means no measurable conduction; it does not distinguish an absent protein from a truncated, mislocalized or non-conducting one. Nor does a cDNA assay reproduce native SCN9A transcript processing or measure transcript and protein abundance in the patient’s neurons: it tests whether the mutant construct produces functional current in the expression system.

The phenotype is not pain alone: Weiss and colleagues (2011) showed that people with the same loss of function are also completely anosmic. The pedigree logic behind reading such families is covered in [pedigrees](https://stemhop.com/lessons/pedigrees/), and why common pain variants need a different design in [complex traits and GWAS](https://stemhop.com/lessons/complex-traits-and-gwas/).

### The same gene, too much pain

**Film transcript: The Same Gene, Too Much Pain**

### Film transcript: The Same Gene, Too Much Pain

Losing this channel removes pain. How could changing the same gene cause too much pain? Variants in the same gene run the other way. These ones alter gating, and their channels are expressed and conducting. In primary erythermalgia, people have burning pain in the hands and feet. The channel protein is there. Something about its gating has gone wrong. In gating terms, what would a sodium channel have to do wrong to cause too much pain?

Three gating changes turn up in pain-associated variants. Open too easily, close too slowly, or fail to inactivate. All three have been found in people, in the same gene. Yang and colleagues found missense variants in a family with erythermalgia, and in a sporadic patient. The next step is the one this field insists on. Take each variant into a recording rig. The recordings were made at about room temperature, where sodium-channel kinetics are slower. Two of those variants were expressed in cultured cells and compared with wild type. Activation was shifted toward more negative voltages. The channel opened where it should be shut. Deactivation was slowed.

Once open, the channel lingered. A channel that opens too easily and closes too late should make its neuron easier to drive. That is an expectation from a cell line, not a recording of the neuron. Paroxysmal extreme pain disorder is a third pattern. Fast inactivation is impaired. What is left behind is persistent sodium current, in three mutant channels tested in vitro. Same gene, three distinct channel lesions, three phenotypes. So one gene can remove pain in one family and cause it in another. These gating measurements came from channels expressed in cultured cells. The pain syndromes themselves were observed and reported in people. And a gating change still has to pass through the neuron before it reaches behaviour.

So the gating step tells you what the protein does. What the neuron does with that is the next film's question. A variant list is not a mechanism. The gating step is where the mechanism starts.

From the film

- Variants in the same gene that alter gating can cause too much pain, as in primary erythermalgia.
- Pain-associated variants can open too easily, close too slowly, or fail to inactivate.
- The gating measurements came from channels in cultured cells, so a gating change still has to pass through the neuron before it reaches behaviour.

Variants in the same gene run the other way. These ones alter how the channel gates, and the channel protein they alter is expressed and conducting — unlike the recessive nonsense constructs, which gave no current above background.

**Predict.** The person has burning pain in the hands and feet, a syndrome called primary erythermalgia. In gating terms, what would the channel have to be doing wrong?

> **Check your prediction.** Three gating changes are each documented in pain-associated Nav1.7 variants: opening at voltages where the channel should be shut, closing too slowly once it has opened, and failing to inactivate so that current persists. Which ones travel together, and with which clinical pattern, is a separate question.
>
> Yang and colleagues (2004) identified SCN9A missense variants in a Chinese primary erythermalgia family and a sporadic patient; Cummins, Dib-Hajj and Waxman then expressed two of them, I848T and L858H, in HEK293 cells at about 21 °C and found activation shifted toward more negative voltages **and** slowed deactivation. In these variants the first two changes came together: a channel that opens at voltages where it should be shut, and lingers. The third change belongs to a different clinical picture. In paroxysmal extreme pain disorder, Fertleman and colleagues (2006) tested three mutant Nav1.7 channels in vitro and found impaired fast inactivation with persistent sodium current. Same gene, distinct channel lesions, distinct phenotypes — and each of these is a measurement on a channel in a cell line, which still has to pass through a neuron before it reaches a symptom.

## Where more current breaks: Nav1.9

**Film transcript: Where More Current Breaks**

### Film transcript: Where More Current Breaks

Two variants both increase one channel's current. Can the neurons do opposite things? The tempting rule is simple. More sodium current means more pain. Nav1.9 breaks it. Its activation and inactivation curves overlap near rest. Near rest, activation and availability overlap, so some channels are open at any moment. The population carries a standing inward current. It is not a spike. It is a steady depolarizing pull on the resting potential. Okuda and colleagues made knock-in mice carrying the variant R222S. That variant is found in familial episodic pain, and their sensory neurons showed increased evoked firing. Huang and colleagues expressed two human variants in small rat sensory neurons.

Those two variants are associated with insensitivity to pain. Both depolarized the neurons and impaired action-potential generation. One of them shifted the average resting potential by about eleven and a half millivolts. Both are gain of channel function. One raises firing. The other impairs it, and in a minority of the most depolarized cells abolishes it. Which should you expect?

You cannot answer from the current alone. You need the availability of the neuron's Nav1.7-like channels. Put the shift on the curve, and the cost shows. Availability falls roughly four-fold. The size depends on the midpoint assumed. The direction does not. Nav1.8 sits on its own curve, far more depolarized. So treat this as a rough, back-of-envelope argument rather than a measurement. A small depolarization brings the membrane closer to threshold. With availability to spare, the neuron can fire more. A larger one takes away the current the upstroke is built from. Only a minority, the cells that depolarized furthest, stopped firing altogether.

So what decides the outcome in the neuron? The outcome depends jointly on the size and time course of the depolarization, subtype-specific availability, channel densities, the other conductances and the stimulation. The channel gains, and the neuron can lose.

Starting availability was not measured and matched between these two preparations. So read this as an account that reconciles two results, not as a measured crossover. Keep the shape of this argument. A channel measurement identifies a channel effect; the neuronal context determines its effect on firing.

From the film

- More sodium current does not always mean more pain, because Nav1.9 carries a standing inward current near rest that depolarizes the neuron.
- Gain-of-function Nav1.9 variants raised firing in one study and impaired it in another, so the current alone cannot predict what the neuron does.
- The outcome depends on the size and time course of the depolarization, subtype-specific availability, channel densities, other conductances and the stimulation.

The tempting rule is that more sodium current means more pain. Nav1.9 breaks it, and watching it break is the most useful thing in this lesson.

Nav1.9 is not built like its neighbours. Its activation and steady-state availability curves overlap near the resting potential, and in that overlap — the **window** — some channels are open at any moment, so the population carries a standing inward current. That window current is the persistent current from the last section: not a spike, but a steady depolarizing pull on the resting potential, which is proposed to set subthreshold excitability.

Now two experiments on the same channel, pointing opposite ways.

- Okuda and colleagues (2016) made [knock-in mice](https://stemhop.com/methods/gene-targeting-mice/) carrying Nav1.9 **R222S**, a variant found in familial episodic pain. Their dorsal root ganglion neurons showed **increased** evoked firing.
- Huang and colleagues (2017) expressed human Nav1.9 **L1302F** and **L811P**, variants associated with insensitivity to pain, in small dorsal root ganglion neurons from rats aged 4 to 6 weeks. Both **depolarized** the neurons and **impaired** action-potential generation; L1302F shifted the average resting potential by 11.5 mV relative to wild-type Nav1.9.

Both are gain of channel function. One raises firing; the other impairs it, and in a minority of the most depolarized cells abolishes it. A proposed reconciliation, before you work for it: different amounts of depolarization, acting on subtype-specific availability and on the rest of the conductance system, can either raise or impair excitability. These preparations were not matched for availability, so the calculation below illustrates one possible cost rather than the measured cause of their difference.

**Predict.** A variant increases a nociceptor’s persistent sodium current, so the resting potential moves 11.5 mV in the positive direction. Does the neuron fire more, or less? Commit before you read on, and notice what you would need to know about the neuron to answer at all.

> **Check your prediction.** You cannot answer from the current alone. You need to know how many of the neuron’s **other** sodium channels are still available.
>
> Put a number on the cost. Take a nociceptor resting at −60 mV, with the same illustrative Nav1.7-like curve, V½ = −65 mV and k = 7 mV:
>
> - at −60 mV: h = 1/(1 + e5/7) = **0.33**, so a third of those channels are available;
> - after an 11.5 mV depolarization, at −48.5 mV: h = 1/(1 + e16.5/7) = **0.086**.
>
> Availability falls about **four-fold**, and the exact factor depends on the midpoint assumed: across plausible V½ values from −60 to −78 mV the loss runs from 3.1-fold to 4.9-fold. The direction does not depend on the assumption; the size does, which is why this is a rough, back-of-envelope argument rather than a measurement. It is also a cost in one subtype only — Nav1.8 is not on this curve — which is one reason not every depolarized cell went silent.
>
> So both outcomes are open to the same channel. A neuron with availability to spare, as at −70 mV in the earlier prediction, can take a small depolarization, move closer to threshold and fire more; that is the pattern proposed for familial episodic pain, as in R222S. A neuron pushed 11.5 mV from −60 mV has given up three-quarters of the availability it had, and loses the current the upstroke is built from; that is the pattern proposed for insensitivity to pain, as in L1302F, where the most depolarized cells stopped firing. The channel gains; the neuron loses.
>
> None of this is a fixed number of millivolts: the arithmetic gives a direction, not a prediction. And the preparations differ in more than availability — a knock-in mouse neuron against a rat neuron transfected with a human channel.

A channel measurement fixes what the protein does; the neuron’s operating point decides what that means for firing. A variant list is not a mechanism.

*Figure (AI-generated illustration).* Human Nav1.9 L1302F expressed in rat dorsal root ganglion neurons depolarized the resting membrane potential and impaired action-potential generation. Strong sustained depolarization reduces the availability of other sodium channels; only the most depolarized cells stopped firing altogether. Separately, dorsal root ganglion neurons from R222S knock-in mice showed increased evoked firing. Nav1.9 gain of function can therefore raise or lower neuronal excitability, depending on the extent of depolarization. Channel symbols and arrows are qualitative and do not represent measured proportions or current ratios. Image: a comparison of human wild-type Nav1.9 and L1302F expressed in rat dorsal root ganglion neurons. Inward sodium current through gold Nav1.9 blocks is shown schematically. L1302F is associated with a less negative resting potential, reduced availability of other sodium channels and impaired action-potential generation, with complete firing failure confined to the most depolarized cells. A separate inset identifies R222S knock-in mouse neurons and increased evoked firing. Channel symbols show illustrative states rather than measured proportions.

## Blocking Nav1.8: from a fitted curve to a spike

**Film transcript: Strong Nav1.8 Block, Still Firing**

### Film transcript: Strong Nav1.8 Block, Still Firing

A drug leaves only a few percent of a channel's current. Does the neuron go quiet? Nav1.7 was the obvious target, and the compound tested here has not delivered. One selective blocker was far more potent on half-inactivated channels than on resting ones. Nearly a thousandfold, produced by voltage alone. That is state dependence of block. It is not selectivity between channel subtypes. In the summarized pharmacology the compound was only elevenfold selective over another subtype. In a trial in painful diabetic neuropathy it did not significantly improve weekly average pain. The healthy-volunteer study's authors proposed insufficient dose and inadequate access to the central nervous system.

Those are candidate causes. Nav1.8 went differently. Suzetrigine binds a site away from the pore and stabilizes the closed state. It was highly selective across the human subtypes tested in a recombinant panel. Selectivity in a recombinant panel is not tissue selectivity in a patient. Two surgical trials, after abdominoplasty and after bunionectomy, summed each patient's pain relief over 48 hours. Suzetrigine beat placebo in both. Neither trial demonstrated superiority over the opioid comparator. A failed superiority test is not equivalence, and one trial's comparator analysis ran the other way. Approval in the United States followed in January 2025, for moderate-to-severe acute pain in adults.

The two drug results came from different pain conditions. They are not a comparison of targets. Now the channel itself. A one-to-one model was fitted to the recombinant current at body temperature. The temperature of the rig changes that fitted number by more than fivefold. At a bath leaving only a few percent of that recombinant current, what does a human neuron do?

Generally, it keeps firing. During depolarizing current injection, most tested neurons kept firing repetitively. Firing was generally reduced, but not eliminated. The peak and the shoulder came down. Threshold and the initial upstroke were largely spared. The voltage-clamp analysis suggested two reasons. In many of these neurons the Nav1.8 current is very large. Near-complete block still leaves nanoampere-level current. And the other channel, Nav1.7, dominates the initial spikes in these recordings. So a channel-current calculation is not neuronal silence. And it is certainly not a dose.

From the film

- Strong Nav1.8 block generally reduced but did not eliminate repetitive firing in adult human sensory neurons recorded at 37 °C.
- A channel-current calculation is not neuronal silence, and it is not a dose.
- Suzetrigine beat placebo in two surgical trials, but neither showed superiority over the opioid comparator, and a failed superiority test is not equivalence.

Here is the opening puzzle in its proper place. Suzetrigine blocks Nav1.8 and reduced pain after surgery versus placebo in both phase 3 trials, while PF-05089771, a selective Nav1.7 blocker, did not beat placebo in painful diabetic neuropathy. Those are different pain conditions, so the two results are not a head-to-head comparison of targets.

Nav1.7 was the obvious target, and the compound tested here has not delivered. It had an IC50 of 11 nM against **half-inactivated** recombinant human Nav1.7 in [HEK293](https://stemhop.com/methods/heterologous-expression/) cells, meaning channels held at a voltage where much of the population has already inactivated, and about 10 μM against the same channels held at rest, nearly a thousandfold difference produced by voltage alone. That difference is the **state dependence of block**: how strongly the drug prefers one channel conformation over another, measured on one channel at two voltages.

State dependence is not selectivity. Selectivity would mean comparing subtypes, and this compound was only 11-fold selective over Nav1.2 in the pharmacology summarized by its healthy-volunteer study. In a [randomized trial](https://stemhop.com/methods/randomized-controlled-trials/) of 135 participants with painful diabetic peripheral neuropathy it did not significantly improve weekly average pain versus placebo at week 4 — which is not a measured absence of effect, only a failure to separate drug from placebo on that endpoint. The authors of the healthy-volunteer study proposed insufficient dose and inadequate access to the central nervous system as candidate explanations, not settled ones. How targets become drugs, and how often they do not, is [drugs against a part](https://stemhop.com/lessons/drugs-against-a-part/).

Nav1.8 went differently. Suzetrigine binds the Nav1.8 voltage-sensing domain 2 **allosterically**, at a site away from the pore, and stabilizes the closed state; it was highly selective over the other human Nav subtypes tested in a recombinant panel, and selectivity in a recombinant panel is not tissue selectivity in a patient. Two phase 3 trials randomized 1,118 adults after abdominoplasty and 1,073 after bunionectomy, with **SPID48** as the outcome: patients rate their pain repeatedly for 48 hours after surgery, and the baseline-relative improvement is summed over that window to give one number per patient, in point-hours. Note what that makes SPID48 — a measure of what patients reported, which is a different kind of evidence from channel, neuronal and animal-withdrawal measurements.

Suzetrigine beat placebo in both trials. Neither trial demonstrated superiority over hydrocodone with acetaminophen, and in the bunionectomy trial’s prespecified comparator analysis SPID48 favoured the opioid. Superiority, non-inferiority and equivalence are three separate hypotheses with separate margins, so a failed superiority test is not equivalence — and here one trial’s comparator analysis ran the other way. United States regulatory approval followed in January 2025 for moderate-to-severe acute pain in adults, an indication broader than the two postoperative surgical models in which the pivotal trials tested it.

**Worked problem.** Stewart and colleagues (2025) fitted a 1:1 concentration-response model to recombinant human Nav1.8 with the beta-3 subunit expressed in CHO cells, obtaining a dissociation constant of 0.38 nM at 37 °C.

> **I(C) = Imax / (1 + C / Kd)**

(a) What fraction of the fitted maximal current remains at 10 nM? (b) What concentration gives 99% inhibition? Work both out before opening the box.

> **Check your answers.** (a) Substituting, f = 0.38 / (0.38 + 10) = 0.0366, so 3.66% remains. Check it the other way: 1 + 10/0.38 = 27.3, and 1/27.3 = 0.0366.
>
> (b) Set f = 0.01: 0.01 = 1 / (1 + C/0.38), so 1 + C/0.38 = 100 and C = 99 × 0.38 = 37.62 nM.
>
> Both answers are ratios to the fitted maximum, so the fitted amplitude cancels.

**Predict.** Now predict what a human nociceptor does in a 10 nM bath.

> **Check your prediction.** Generally, it keeps firing. In dissociated dorsal root ganglion neurons from adult human organ donors recorded at 37 °C, suzetrigine generally reduced but did not eliminate repetitive firing, and at 10 nM it reduced the action-potential peak and shoulder while largely sparing threshold and the initial upstroke. Read the protocol with the result: the spikes were evoked by depolarizing current injection, in most of the neurons tested. The bath concentration on its own does not tell you what any individual neuron will do.
>
> The authors’ voltage-clamp analysis suggested two possible reasons: many of these neurons carry such large Nav1.8 currents that even 99% inhibition leaves nanoampere-level current, and Nav1.7 current dominates the initial spikes in these recordings and could also contribute to repetitive firing.

Slide the concentration yourself, and predict the residual current before you read it off.

*Interactive on the lesson page:* Residual current from a fitted curve

**Back to the opening puzzle.** These results illustrate the gap between genetic requirement and pharmacological efficacy; the causes of their different clinical outcomes remain unresolved. Human genetics names a channel the behaviour requires. That is a statement about the neuron, not a promise that a drug can occupy enough of that channel, in the right conformation, in the tissue where it matters — and, as the human recordings show, even strong occupancy of the right channel need not silence a nociceptor. A clean genetic requirement and a useful drug are two different achievements.

## Which nociceptors? Labels, classes and states

**Film transcript: Labels, Classes and States**

### Film transcript: Labels, Classes and States

Textbooks sort nociceptors into tidy bins. What are those bins actually measuring? Three unrelated kinds of measurement are being mixed: a molecular label, a conduction class, and a functional state. A molecular label is a gene whose expression marks a population and gives genetic access to it. These are markers, not functions. CGRP is not a heat channel. A conduction class is a velocity measured from an axon. Mouse high-threshold mechanonociceptors with circumferential hair-follicle endings carried a peptidergic label. Their label encodes alpha-CGRP, so a mechanonociceptor sits in a peptidergic class. The axes cross. A functional state is something a neuron can change.

Some labelled nociceptors were mechanically silent. After a day with nerve growth factor, mechanically activated currents appeared. Knockdown of PIEZO2 prevented them from appearing, so it was required for the change. a dish, and in the soma rather than the ending. Neither result came from an intact ending. Now remove a whole labelled population in an adult animal and test behaviour. Histology showed that the treatment eliminated more than ninety-eight percent of the labelled cell bodies. Mechanical withdrawal threshold rose, while heat and cold responses were spared in the ranges tested. A lesion of TRPV1-positive central branches did the opposite.

Noxious heat responses went, and baseline mechanical thresholds were unchanged. Read together, that is a functional dissociation in mice, in those stimulus ranges. It is not evidence that every fibre is unimodal, nor that mouse withdrawal reports human pain. Adult removal moved one modality. Predict what happens when the same neurons are deleted from birth.

Nothing detectable. The mice deleted from birth lacked a mechanical deficit in the later assays. So a germline deletion is a developmental experiment, and an adult manipulation asks a different question. These mouse and cellular experiments measure channels, neurons and reflexes. The lesson's surgical trials measure what patients reported. Keep those levels of evidence distinct.

From the film

- A molecular label, a conduction class and a functional state are different kinds of measurement, so nociceptor categories overlap.
- In mice, removing one labelled population in adults raised mechanical thresholds while sparing heat and cold in the ranges tested, and a TRPV1-positive lesion did the opposite.
- Deleting the same neurons from birth showed no detectable mechanical deficit, so a germline deletion is a developmental experiment.

The same discipline applies one level up, to populations. Textbook figures still divide nociceptors into bins: peptidergic, non-peptidergic, Aδ, C. The experiments of the last fifteen years do not support bins, because the categories come from three unrelated kinds of measurement.

A **molecular label** is a gene whose expression marks a population and gives genetic access to it. Cavanaugh and colleagues used CGRP as a marker of peptidergic afferents in mouse tissue, and the Mrgprd-positive population they studied binds the plant lectin IB4, the classical non-peptidergic stain. These are markers, not functions: CGRP is not a heat channel.

A **conduction class** is a velocity measured from an axon. Ghitani and colleagues identified mouse Aδ high-threshold mechanonociceptors whose endings wrap circumferentially around hair follicles, and their medium-diameter neurons were Calca-labelled, with conduction velocity measured in vivo. Calca encodes alpha-CGRP (and calcitonin, by alternative splicing). So a mechanonociceptor carries a peptidergic label, and the two axes cross.

A **functional state** is something a neuron can change. Prato and colleagues identified CHRNA3-positive mechanoinsensitive peptidergic C-fibre nociceptors in cultured lumbar dorsal root ganglion neurons from mice aged 8 to 12 weeks. Take the three conditions one at a time. Untreated, almost none of these neurons gave a mechanically activated current when the soma was indented. After 24 hours with 50 ng/ml nerve growth factor, the currents appeared. With the growth factor plus [siRNA](https://stemhop.com/methods/rnai-knockdown/) knockdown of PIEZO2, they did not. So in a dish, and in the soma rather than an intact ending, silence was a state rather than a property, and PIEZO2 was required for the change.

*Figure (AI-generated illustration).* Soma-indentation experiments in cultured mouse dorsal root ganglion neurons show that mechanical silence can change. CHRNA3-positive peptidergic neurons were almost unresponsive before treatment; one of fifteen tested cells showed a tiny inward current. After 24 hours with nerve growth factor, mechanically activated currents appeared, and siRNA knockdown of PIEZO2 prevented their appearance. CHRNA3 marks a nicotinic receptor subunit and serves only as an identifying label for the population; these experiments establish a requirement for PIEZO2 in the induced current, not a mechanism demonstrated in intact nerve endings. Image: three conditions in cultured mouse CHRNA3-positive dorsal root ganglion neuron somata. Indentation before treatment produces essentially no current, with a tiny response in one of fifteen tested cells. After 24 hours with NGF, indentation evokes inward current. With NGF and PIEZO2 siRNA knockdown, the induced current does not appear. The drawings show separate experimental conditions, not repeated measurements of one tracked neuron.

The transcriptomic census that these labels came out of belongs to [the atlas lesson](https://stemhop.com/lessons/sensory-neuron-atlas/), and the thermal channels to [thermosensation](https://stemhop.com/lessons/thermosensation/).

## Ablate one population, lesion another

The cleanest way to ask what a molecularly defined population does is to remove it in an adult and test behaviour. Cavanaugh and colleagues (2009) did this in mice carrying a [diphtheria toxin](https://stemhop.com/methods/targeted-cell-ablation/) receptor in Mrgprd-positive neurons, and they did the control that makes the result readable: histology showed that toxin treatment eliminated more than 98% of Mrgprd-positive dorsal root ganglion cell bodies.

Behaviour then moved in one modality. Mechanical withdrawal threshold, measured with calibrated [von Frey](https://stemhop.com/methods/rodent-behavioural-assays/) filaments, rose, while responses to heat and cold were spared within the tested stimulus ranges. The complementary experiment went the other way and used a different tool: a pharmacological lesion of TRPV1-positive central afferent branches abolished noxious heat sensitivity in those assays while baseline mechanical withdrawal thresholds were unchanged. Note that the lesion is defined by transient receptor potential vanilloid 1 (TRPV1) expression and placed at the central branches, which transmit the afferent signal rather than transduce heat at the skin. Read the two together and you have a functional dissociation in mice, in those stimulus ranges — not evidence that every individual fibre is unimodal, nor that mouse withdrawal reports human pain.

The third arm is the one most often dropped. Mice whose Mrgprd-positive neurons were deleted from birth lacked a detectable mechanical deficit in the later assays, which the authors read as compensation. Every genetic result in this field inherits that problem: a germline deletion is a developmental experiment, while adult manipulations — induced gene deletion, cell ablation, reversible silencing, acute pharmacology — ask what the adult circuit needs, and the two can disagree completely about the same cells.

### Design problem

Mice lacking Nav1.7 are analgesic, and three groups explain it differently. Minett, Wood and colleagues (2015) found upregulation of Penk, the proenkephalin gene whose product yields endogenous opioid peptides, and substantial naloxone reversal in conditional nulls aged 8 to 12 weeks, plus one 39-year-old woman in whom naloxone raised detection of brief heat pulses from none to 80%. MacDonald and colleagues (2021) reported an opioid-dependent reduction of transmission at nociceptor central terminals, the second route: release rather than spike initiation. Deng and colleagues (2023) localized the enkephalin increase to C-low-threshold mechanoreceptors, the unmyelinated afferents that respond to gentle stroking rather than to noxious stimuli, found it unnecessary for the analgesia, and showed Nav1.7 is required for C-fibre spike initiation. Design experiments to separate these.

> **One way to do it.** Match the variables that differ before testing the mechanism.
>
> 1. **Timing.** Run the same assay on a developmental deletion and on a tamoxifen-induced adult deletion in the same driver line. The Mrgprd ablation result above shows how far these can diverge for one population.
> 2. **Deletion pattern.** Cre drivers determine where, and for inducible drivers when, the floxed gene is recombined, and the three studies did not use the same ones: Advillin-Cre, which targets sensory neurons; Wnt1-Cre, which targets neural-crest derivatives more broadly; and the full-body tamoxifen-inducible ERT-Cre knockout used by Deng and colleagues. Their deletion patterns have to be measured rather than assumed equivalent. Cross each driver to a reporter, score which populations recombine, and repeat the naloxone challenge in matched patterns before comparing outcomes.
> 3. **Recording site.** Behaviour cannot distinguish a failure to initiate a spike from a failure to release at the terminal. Record at both: in vivo C-fibre recordings for initiation, and dorsal horn synaptic transmission for the terminal, in the same animals.
> 4. **Opioid arm.** Include genotype-by-antagonist controls, blinding, and a positive control showing naloxone works in that preparation. Endogenous opioid dependence here means a mechanism inside the animal, with nothing to do with addiction.
> 5. **Scope.** The human evidence is three Nav1.7-null participants: the woman reported in 2015, and two men in MacDonald and colleagues (2021). Naloxone enhanced pain sensitivity in the woman and in one of the two men, and had no apparent effect in the other, so the positive tally is two of three. That is informative and not decisive. A mechanistic claim about people needs a larger cohort with a measured opioid manipulation.
>
> The result that would settle most of it: an adult-induced, nociceptor-restricted deletion with the enkephalin increase blocked, tested for analgesia and recorded at both the initiation site and the terminal.

### Where the idea stops

- **It is a rule about spike initiation, and spike initiation is not the only route.** Transmitter release at the central terminal can change while peripheral firing is preserved, which is what the design problem turns on.
- **Keep the levels of evidence apart.** The channel recordings, the neuronal recordings and the mouse withdrawal assays do not report what anyone feels; the human studies and clinical phenotypes do include reports of pain, and the surgical trials quantify them with SPID48. Connecting a channel to a report takes every step in between.
- **Availability gives a direction, not an outcome.** It is one subtype’s reserve, measured at steady state, and firing also depends on the size of the depolarization, a threshold that can move and the rest of the neuron’s conductances.
- **Block is not silence.** A fitted concentration-response curve describes a recombinant current. Whether a neuron stops firing is a separate measurement, and in human neurons it generally did not.
- **A label is not a function, and a deletion carries its timing.** Marker genes give access to populations; what those populations do has to be measured, in adults as well as from birth.

## Going deeper

### Resting potential and spike threshold

Huang and colleagues offer an account that reconciles the two directions of the Nav1.9 story. In non-transfected rat dorsal root ganglion neurons held at a range of membrane potentials, the minimum injected current needed to evoke a spike varied non-monotonically: it fell with a few millivolts of depolarization and rose again with more. That is the measured counterpart of the account above. Note what it was — the current needed to fire a cell in one preparation, not a universal relation between resting potential and voltage threshold. Where the bottom of that curve sits, and whether another neuron shows a useful dip, requires measurement or a model that includes the relevant conductances and the stimulation protocol; starting availability alone does not locate it.

### The suzetrigine trial numbers

In phase 2, only the highest tested regimen reduced postoperative pain versus placebo over 48 hours. In phase 3, the abdominoplasty SPID48 difference versus placebo was 48.4 point-hours (95% CI 33.6 to 63.1); the bunionectomy difference versus placebo was smaller, 29.3 point-hours (95% CI 14.0 to 44.6), and in that trial’s prespecified comparator analysis SPID48 favoured hydrocodone with acetaminophen by 20.2 point-hours (95% CI 7.7 to 32.7).

### Suzetrigine’s selectivity panel

The reported figure is at least 31,000-fold selectivity over the other tested human Nav subtypes, measured in a recombinant panel.

### PF-05089771 in healthy volunteers

In a crossover study of 25 healthy males aged 18 to 55, a single 300 mg dose did not differ from placebo on the primary endpoints. That study is also the source of the pharmacology summary quoted above.

### The anosmia, and what differs between mice

In mice the olfactory failure is opioid independent while the analgesia is naloxone reversible (MacDonald and colleagues 2021).

### Numbers behind the nociceptor axes

Ghitani and colleagues’ medium-diameter Calca-labelled neurons conducted at 3.6 ± 0.47 m/s on average in a sample of six in vivo extracellular recordings, which the authors classified as Aδ in that preparation, against a slower small-diameter comparison group in the C-fibre range. Where the boundary between the classes falls depends on the species and the recording conditions, so a velocity is read against the criteria of the study that measured it. CHRNA3-positive neurons were about 7.8 ± 1.6% of cells in cultured mouse L2 to L5 preparations, and about half of retrogradely traced peptidergic afferents innervating the visceral and deep somatic tissues the authors examined. Denominators travel with their tissue: neither is a count of cutaneous nociceptors, and neither is a human proportion.

### The Mrgprd ablation in numbers

In the mice with adult ablation of Mrgprd-positive neurons, mechanical withdrawal threshold rose from 0.41 ± 0.04 g to 0.99 ± 0.15 g (mean ± SEM).

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/nociceptors-and-sodium-channels/
